The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
In Science this week: effort to reduce E. coli genome, and more.
The Scientist traces the career path of the J. Craig Venter Institute's Clyde Hutchinson.
The firm is developing protein therapies incorporating synthetic amino acids coded for by "unnatural" base pairs developed at The Scripps Research Institute.
The company said it will use the proceeds to fund its growth into new markets, and to build its next-generation automated foundry.
Researchers and business leaders unveil their plan for HGP-write to synthesize full genomes.
A proposal published in Science lays out a vision to drive down the cost of fabricating genomes and accelerate research and innovation in synthetic biology.
At a user meeting in London this week, Chief Technology Officer Clive Brown introduced the SmidgIon and a number of other technology developments, as well as a new synthetic biology spinoff.
Harvard's George Church says that a project to create synthetic human genomes at the center of last week's controversial meeting is at the 'thought experiment' stage.
Twist said it will use Genome Compiler's technology and expertise to build a portfolio of digital products, including a suite of gene design products.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.